[go: up one dir, main page]

SG11202100303QA - Methods for the administration of certain vmat2 inhibitors - Google Patents

Methods for the administration of certain vmat2 inhibitors

Info

Publication number
SG11202100303QA
SG11202100303QA SG11202100303QA SG11202100303QA SG11202100303QA SG 11202100303Q A SG11202100303Q A SG 11202100303QA SG 11202100303Q A SG11202100303Q A SG 11202100303QA SG 11202100303Q A SG11202100303Q A SG 11202100303QA SG 11202100303Q A SG11202100303Q A SG 11202100303QA
Authority
SG
Singapore
Prior art keywords
administration
methods
vmat2 inhibitors
certain
certain vmat2
Prior art date
Application number
SG11202100303QA
Inventor
Grace S Liang
Christopher O'brien
Dao Tuyet Thai-Cuarto
Original Assignee
Neurocrine Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=69525823&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11202100303Q(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Neurocrine Biosciences Inc filed Critical Neurocrine Biosciences Inc
Publication of SG11202100303QA publication Critical patent/SG11202100303QA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
SG11202100303QA 2018-08-15 2019-08-14 Methods for the administration of certain vmat2 inhibitors SG11202100303QA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862764889P 2018-08-15 2018-08-15
US201862719369P 2018-08-17 2018-08-17
PCT/US2019/046462 WO2020037022A1 (en) 2018-08-15 2019-08-14 Methods for the administration of certain vmat2 inhibitors

Publications (1)

Publication Number Publication Date
SG11202100303QA true SG11202100303QA (en) 2021-02-25

Family

ID=69525823

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202100303QA SG11202100303QA (en) 2018-08-15 2019-08-14 Methods for the administration of certain vmat2 inhibitors

Country Status (16)

Country Link
US (1) US11026931B2 (en)
EP (1) EP3836926A4 (en)
JP (4) JP2021528481A (en)
KR (1) KR20210044817A (en)
CN (1) CN112867491A (en)
AU (1) AU2019322863B2 (en)
BR (1) BR112021000019A2 (en)
CA (1) CA3104693A1 (en)
IL (2) IL320987A (en)
JO (1) JOP20200336A1 (en)
MA (1) MA53239A (en)
MX (1) MX2021001017A (en)
PH (1) PH12021550302A1 (en)
SG (1) SG11202100303QA (en)
TW (1) TW202021585A (en)
WO (1) WO2020037022A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX381258B (en) 2015-10-30 2025-03-12 Neurocrine Biosciences Inc VALBENAZINE SALTS AND POLYMORPHS THEREOF.
US10160757B2 (en) 2015-12-23 2018-12-25 Neuroscrine Biosciences, Inc. Synthetic methods for preparation of (S)-(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate)
EA201991786A1 (en) 2017-01-27 2020-01-16 Нейрокрин Байосайенсиз, Инк. METHODS FOR INTRODUCING SOME VMAT2 INHIBITORS
IL301770B2 (en) 2017-09-21 2024-06-01 Neurocrine Biosciences Inc High dosage valbenazine formulation and compositions, methods, and kits related thereto
KR20250070134A (en) 2017-10-10 2025-05-20 뉴로크린 바이오사이언시즈 인코퍼레이티드 Methods for the administration of certain vmat2 inhibitors
MY198713A (en) 2017-10-10 2023-09-19 Neurocrine Biosciences Inc Methods for the administration of certain vmat2 inhibitors
SG11202100303QA (en) 2018-08-15 2021-02-25 Neurocrine Biosciences Inc Methods for the administration of certain vmat2 inhibitors
MX2021013132A (en) * 2019-05-09 2021-11-25 Neurocrine Biosciences Inc Methods for the administration of certain vmat2 inhibitors.
US10940141B1 (en) 2019-08-23 2021-03-09 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors
MX2022015742A (en) * 2020-06-10 2023-01-19 Auspex Pharmaceuticals Inc Osmotic dosage forms comprising deutetrabenazine and methods of use thereof.
TW202322816A (en) 2021-08-20 2023-06-16 美商紐羅克里生物科學有限公司 Methods of screening for vmat2 inhibitors
TW202521119A (en) 2023-08-17 2025-06-01 美商紐羅克里生物科學有限公司 Methods for the administration of certain vmat2 inhibitors
WO2025038959A1 (en) 2023-08-17 2025-02-20 Neurocrine Biosciences, Inc. Methods for the administration of certain vmat2 inhibitors

Family Cites Families (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
JPS5777697A (en) 1980-11-04 1982-05-15 Nippon Zoki Pharmaceut Co Ltd Physiologically active substance nsq
US4328245A (en) 1981-02-13 1982-05-04 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4410545A (en) 1981-02-13 1983-10-18 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
JPS57209225A (en) 1981-06-18 1982-12-22 Yamasa Shoyu Co Ltd Antitumor activity intensifier
US4409239A (en) 1982-01-21 1983-10-11 Syntex (U.S.A.) Inc. Propylene glycol diester solutions of PGE-type compounds
KR890002631B1 (en) 1984-10-04 1989-07-21 몬산토 캄파니 Composition of prolonged release of biologically active somatotropin
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
US5612059A (en) 1988-08-30 1997-03-18 Pfizer Inc. Use of asymmetric membranes in delivery devices
IT1229203B (en) 1989-03-22 1991-07-25 Bioresearch Spa USE OF 5 METHYLTHETRAHYDROPHOLIC ACID, 5 FORMYLTHETRAHYDROPHOLIC ACID AND THEIR PHARMACEUTICALLY ACCEPTABLE SALTS FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS IN THE FORM OF CONTROLLED RELEASE ACTIVE IN THE THERAPY OF MENTAL AND ORGANIC DISORDERS.
PH30995A (en) 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5585112A (en) 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
IT1246382B (en) 1990-04-17 1994-11-18 Eurand Int METHOD FOR THE TARGETED AND CONTROLLED DELIVERY OF DRUGS IN THE INTESTINE AND PARTICULARLY IN THE COLON
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5204329A (en) 1990-06-11 1993-04-20 Du Pont Merck Pharmaceutical Company Treatment of organ transplantation rejection
US5543390A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
TW333456B (en) 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US6274552B1 (en) 1993-03-18 2001-08-14 Cytimmune Sciences, Inc. Composition and method for delivery of biologically-active factors
US5523092A (en) 1993-04-14 1996-06-04 Emory University Device for local drug delivery and methods for using the same
US5985307A (en) 1993-04-14 1999-11-16 Emory University Device and method for non-occlusive localized drug delivery
US6087324A (en) 1993-06-24 2000-07-11 Takeda Chemical Industries, Ltd. Sustained-release preparation
US6004534A (en) 1993-07-23 1999-12-21 Massachusetts Institute Of Technology Targeted polymerized liposomes for improved drug delivery
IT1270594B (en) 1994-07-07 1997-05-07 Recordati Chem Pharm CONTROLLED RELEASE PHARMACEUTICAL COMPOSITION OF LIQUID SUSPENSION MOGUISTEIN
US5759542A (en) 1994-08-05 1998-06-02 New England Deaconess Hospital Corporation Compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases
US5660854A (en) 1994-11-28 1997-08-26 Haynes; Duncan H Drug releasing surgical implant or dressing material
US6316652B1 (en) 1995-06-06 2001-11-13 Kosta Steliou Drug mitochondrial targeting agents
US5798119A (en) 1995-06-13 1998-08-25 S. C. Johnson & Son, Inc. Osmotic-delivery devices having vapor-permeable coatings
DE69632684T2 (en) 1995-06-27 2005-06-09 Takeda Pharmaceutical Co. Ltd. PROCESS FOR PREPARING PREPARED DELETION PREPARATIONS
TW448055B (en) 1995-09-04 2001-08-01 Takeda Chemical Industries Ltd Method of production of sustained-release preparation
JP2909418B2 (en) 1995-09-18 1999-06-23 株式会社資生堂 Delayed release microsphere of drug
US6039975A (en) 1995-10-17 2000-03-21 Hoffman-La Roche Inc. Colon targeted delivery system
US5980945A (en) 1996-01-16 1999-11-09 Societe De Conseils De Recherches Et D'applications Scientifique S.A. Sustained release drug formulations
TW345603B (en) 1996-05-29 1998-11-21 Gmundner Fertigteile Gmbh A noise control device for tracks
US6264970B1 (en) 1996-06-26 2001-07-24 Takeda Chemical Industries, Ltd. Sustained-release preparation
US6419961B1 (en) 1996-08-29 2002-07-16 Takeda Chemical Industries, Ltd. Sustained release microcapsules of a bioactive substance and a biodegradable polymer
ZA977967B (en) 1996-09-23 1999-03-04 Lilly Co Eli Combination therapy for treatment of psychoses
US6139865A (en) 1996-10-01 2000-10-31 Eurand America, Inc. Taste-masked microcapsule compositions and methods of manufacture
CA2217134A1 (en) 1996-10-09 1998-04-09 Sumitomo Pharmaceuticals Co., Ltd. Sustained release formulation
ATE272394T1 (en) 1996-10-31 2004-08-15 Takeda Chemical Industries Ltd DELAYED RELEASE PREPARATION
US6131570A (en) 1998-06-30 2000-10-17 Aradigm Corporation Temperature controlling device for aerosol drug delivery
ZA9711385B (en) 1996-12-20 1999-06-18 Takeda Chemical Industries Ltd Method of producing a sustained-release preparation
US5891474A (en) 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
US6120751A (en) 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
US6060082A (en) 1997-04-18 2000-05-09 Massachusetts Institute Of Technology Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery
US6350458B1 (en) 1998-02-10 2002-02-26 Generex Pharmaceuticals Incorporated Mixed micellar drug deliver system and method of preparation
US6613358B2 (en) 1998-03-18 2003-09-02 Theodore W. Randolph Sustained-release composition including amorphous polymer
US6048736A (en) 1998-04-29 2000-04-11 Kosak; Kenneth M. Cyclodextrin polymers for carrying and releasing drugs
KR19990085365A (en) 1998-05-16 1999-12-06 허영섭 Biodegradable polymer microspheres capable of continuously controlled controlled release and preparation method thereof
WO2000024399A1 (en) 1998-10-23 2000-05-04 Sepracor Inc. Compositions and methods employing r(-) fluoxetine and other active ingredients
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6271359B1 (en) 1999-04-14 2001-08-07 Musc Foundation For Research Development Tissue-specific and pathogen-specific toxic agents and ribozymes
CA2420535A1 (en) 2000-08-30 2002-03-07 Mary Tanya Am Ende Sustained release formulations for growth hormone secretagogues
AU2003240818B2 (en) 2002-05-28 2006-05-04 Bette Pollard Cardiac glycosides to treat cystic fibrosis and other IL-8 dependent disorders
CA2499601A1 (en) 2002-09-19 2004-04-01 University Of Utah Research Foundation Modulating vesicular monoamine transporter trafficking and function: a novel approach for the treatment of parkinson's disease
GB2410947B (en) 2004-02-11 2008-09-17 Cambridge Lab Ltd Pharmaceutical compounds
EP1753455A2 (en) * 2004-06-04 2007-02-21 Genentech, Inc. Method for treating multiple sclerosis
DK1855677T3 (en) 2005-08-06 2009-02-09 Cambridge Lab Ireland Ltd 3.11 B-CIS dihydrotetrabenzene for the treatment of schizophrenia and other psychoses
US20100076087A1 (en) * 2005-10-06 2010-03-25 Auspex Pharmaceuticals, Inc. Methods of reduction of interpatient variability
CA2668689C (en) 2006-11-08 2015-12-29 Neurocrine Biosciences Inc. Substituted 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2h-pyrido[2,1-a]isoquinolin-2-ol compounds and methods relating thereto
GB0721669D0 (en) 2007-11-02 2007-12-12 Cambridge Lab Ireland Ltd Pharmaceutical compounds
CN101910143B (en) 2008-01-18 2013-08-21 卫材R&D管理有限公司 Fused Aminodihydrothiazine Derivatives
US20110053866A1 (en) 2008-08-12 2011-03-03 Biovail Laboratories International (Barbados) S.R.L. Pharmaceutical compositions
GB2462611A (en) 2008-08-12 2010-02-17 Cambridge Lab Pharmaceutical composition comprising tetrabenazine
WO2011019956A2 (en) 2009-08-12 2011-02-17 Biovail Laboratories International (Barbados) S.R.L. Pharmaceutical compositions
GB2463452A (en) 2008-09-08 2010-03-17 Cambridge Lab Desmethyl derivatives of tetrabenazine and pharmaceutical compositions thereof
GB2463451A (en) 2008-09-08 2010-03-17 Cambridge Lab 3, 11b cis-dihydrotetrabenazine compounds for use in the treatment of dementia
EP2610254B1 (en) 2008-09-18 2015-11-25 Auspex Pharmaceuticals, Inc. Deuterated benzoquinoline derivatives as inhibitors of vesicular monoamine transporter 2
US20100096319A1 (en) 2008-10-17 2010-04-22 General Electric Company Separator assembly
CN104744456A (en) * 2010-06-01 2015-07-01 奥斯拜客斯制药有限公司 Benzoquinolone inhibitors of VMAT2
CN104684555A (en) 2012-09-18 2015-06-03 奥斯拜客斯制药有限公司 Formulation pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
BR112015014619A2 (en) 2012-12-18 2017-07-11 Vanda Pharmaceuticals Inc treatment of circadian rhythm disorders
JP2016506957A (en) 2013-01-31 2016-03-07 オースペックス・ファーマシューティカルズ・インコーポレイテッドＡｕｓｐｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． VMAT2 benzoquinolone inhibitor
WO2015077521A1 (en) 2013-11-22 2015-05-28 Auspex Pharmaceuticals, Inc. Benzoquinoline inhibitors of vesicular monoamine transporter 2
EP3099299A4 (en) 2014-01-27 2017-10-04 Auspex Pharmaceuticals, Inc. Benzoquinoline inhibitors of vesicular monoamine transporter 2
RU2021128797A (en) * 2014-02-07 2021-11-26 Ньюрокрайн Байосайенсиз, Инк. PHARMACEUTICAL COMPOSITIONS CONTAINING ANTIPSYCHOTIC DRUG AND VMAT2 INHIBITOR AND THEIR APPLICATION
KR20160117596A (en) 2014-02-07 2016-10-10 오스펙스 파마슈티칼스, 인코포레이티드 Novel pharmaceutical formulations
JP6635945B2 (en) 2014-05-06 2020-01-29 ニューロクライン バイオサイエンシーズ，インコーポレイテッド VMAT2 inhibitor for treating hyperkinetic movement disorder
CA2974540C (en) 2015-02-06 2023-09-26 Neurocrine Biosciences, Inc. [9,10-dimethoxy-3-(2-methylpropyl)-1h,2h,3h,4h,6h,7h,11bh-pyrido-[2,1-a]isoquinolin-2-yl]methanol and compounds, compositions and methods relating thereto
PL3265085T3 (en) 2015-03-06 2022-11-07 Auspex Pharmaceuticals, Inc. Methods for the treatment of abnormal involuntary movement disorders
WO2016210180A2 (en) 2015-06-23 2016-12-29 Neurocrine Biosciences, Inc. Vmat2 inhibitors for treating neurological diseases or disorders
MX381258B (en) 2015-10-30 2025-03-12 Neurocrine Biosciences Inc VALBENAZINE SALTS AND POLYMORPHS THEREOF.
US10160757B2 (en) 2015-12-23 2018-12-25 Neuroscrine Biosciences, Inc. Synthetic methods for preparation of (S)-(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate)
EP4400171A3 (en) 2016-12-02 2024-09-11 Neurocrine Biosciences, Inc. Use of valbenazine for treating schizophrenia or schizoaffective disorder
EA201991786A1 (en) 2017-01-27 2020-01-16 Нейрокрин Байосайенсиз, Инк. METHODS FOR INTRODUCING SOME VMAT2 INHIBITORS
CA3057548A1 (en) 2017-04-01 2018-10-04 Adeptio Pharmaceuticals Limited Pharmaceutical compositions
CN110678181A (en) 2017-04-01 2020-01-10 阿德普蒂奥制药有限公司 Use of (+)-α-dihydrotetrabenazine in the treatment of dyskinesia
JOP20190239A1 (en) 2017-04-19 2019-10-09 Neurocrine Biosciences Inc Vmat2 inhibitor compounds and compositions thereof
WO2018200605A1 (en) 2017-04-26 2018-11-01 Neurocrine Biosciences, Inc. Use of valbenazine for treating levodopa-induced dyskinesia
IL301770B2 (en) 2017-09-21 2024-06-01 Neurocrine Biosciences Inc High dosage valbenazine formulation and compositions, methods, and kits related thereto
MY198713A (en) 2017-10-10 2023-09-19 Neurocrine Biosciences Inc Methods for the administration of certain vmat2 inhibitors
KR20250070134A (en) 2017-10-10 2025-05-20 뉴로크린 바이오사이언시즈 인코퍼레이티드 Methods for the administration of certain vmat2 inhibitors
EP3713938A1 (en) 2017-11-22 2020-09-30 Assia Chemical Industries Ltd Solid state form of valbenazine
WO2019241555A1 (en) 2018-06-14 2019-12-19 Neurocrine Biosciences, Inc. Vmat2 inhibitor compounds, compositions, and methods relating thereto
SG11202100303QA (en) 2018-08-15 2021-02-25 Neurocrine Biosciences Inc Methods for the administration of certain vmat2 inhibitors
MX2021013132A (en) 2019-05-09 2021-11-25 Neurocrine Biosciences Inc Methods for the administration of certain vmat2 inhibitors.
US10689380B1 (en) 2019-07-30 2020-06-23 Farmhispania S.A. Crystalline forms of valbenazine ditosylate
US10940141B1 (en) 2019-08-23 2021-03-09 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors

Also Published As

Publication number Publication date
US11026931B2 (en) 2021-06-08
MA53239A (en) 2022-05-04
CA3104693A1 (en) 2020-02-20
WO2020037022A1 (en) 2020-02-20
BR112021000019A2 (en) 2021-04-06
US20200360354A1 (en) 2020-11-19
CN112867491A (en) 2021-05-28
AU2019322863A1 (en) 2021-03-11
TW202021585A (en) 2020-06-16
JOP20200336A1 (en) 2020-12-22
KR20210044817A (en) 2021-04-23
MX2021001017A (en) 2021-04-19
IL320987A (en) 2025-07-01
JP2024113044A (en) 2024-08-21
PH12021550302A1 (en) 2021-10-25
JP2021183641A (en) 2021-12-02
IL279662A (en) 2021-03-01
EP3836926A4 (en) 2022-05-04
AU2019322863B2 (en) 2025-02-27
JP2022168146A (en) 2022-11-04
JP2021528481A (en) 2021-10-21
EP3836926A1 (en) 2021-06-23

Similar Documents

Publication Publication Date Title
IL279662A (en) Methods for the administration of certain vmat2 inhibitors
SG11202003194YA (en) Methods for the administration of certain vmat2 inhibitors
IL287902A (en) Methods for the administration of certain vmat2 inhibitors
IL321844A (en) Inhibitors of the menin-mll interaction
PL3512850T3 (en) Inhibitors of the menin-mll interaction
IL248745A0 (en) Vmat2 inhibitors for the treatment of hyperkinetic movement disorders
IL276269A (en) Aminopyrrolotriazines as kinase inhibitors
EP3906029A4 (en) Inhibitors of menin-mll interaction
SG11202010024UA (en) New quinoline derivatives
EP3265093A4 (en) Tricyclic kinase inhibitors of melk and methods of use
IL281634A (en) N-substituted-dioxocyclobutenylamino-3-hydroxy-picolinamides useful as ccr6 inhibitors
IL276592A (en) Derivatives of sobetirome
IL276013A (en) Pi4kiiibeta inhibitors
SG11202102379XA (en) O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors
IL283273A (en) Pharmaceutical methods
IL281599A (en) Tyk2 kinase inhibitors
IL307678A (en) Methods for the administration of certain vmat2 inhibitors
IL280312A (en) Process for the preparation of bromodomain inhibitor
IL274415A (en) Ezh2 inhibitor combination therapies
SG11202101817UA (en) Methods of inhibition
HK40052114A (en) Methods for the administration of certain vmat2 inhibitors
GB201807845D0 (en) Kinase Inhibitors
HK40061236A (en) Methods for the administration of certain vmat2 inhibitors
HK40055590A (en) Methods of inhibition
GB201812462D0 (en) Inhibitors